|
|
|
|
MS Choudhary, N Sachs, A Uluer, RA Glennon, RB Westkaemper and BL Roth
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106.
In this paper we show that a highly conserved aromatic residue, phenylalanine at the 340-position, is essential for ergoline binding to 5-hydroxytryptamine2A receptors. We hypothesized that F340 was essential for a specific aromatic-aromatic interaction (e.g., pi-pi or hydrophobic) between the phenyl moiety of F340 and the aromatic ring of the ergoline nucleus. To test this hypothesis, eight point mutations of adjacent (F340 and F339) and nonadjacent (F125) phenylanaines were made, using conservative (phenylalanine to tyrosine) and nonconservative (phenylalanine to leucine, alanine, or serine) substitutions. The binding affinities of all of the tested simple ergolines were greatly reduced by specific mutations of F340 in which aromatic-aromatic interactions (e.g., F340A and F340L) were abolished, but they were unaffected when the replacement residue was aromatic (e.g., F340Y). In contrast, the binding affinities of four ergopeptines (bromocryptine, ergocryptine, ergocornine, and ergotamine) were relatively unaffected by the F340L substitution. Neither ergoline nor ergopeptine affinities were consistently altered by F339 mutations. These results support the notion that aromatic-aromatic interactions (either pi-pi of hydrophobic) with F340 are essential for the binding of simple ergolines but not ergopeptines to 5-hydroxytryptamine2A receptors. Our findings support models of ergoline and ergopeptine binding to serotonin receptors that suggest that the nature of the substituent at the 8-position of the ergoline nucleus may give rise to different modes of binding for the two classes of agents, particularly with respect to the phenyl ring of F340.
This article has been cited by other articles:
![]() |
M. R. Braden and D. E. Nichols Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor Mol. Pharmacol., November 1, 2007; 72(5): 1200 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Braden, J. C. Parrish, J. C. Naylor, and D. E. Nichols Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists Mol. Pharmacol., December 1, 2006; 70(6): 1956 - 1964. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Clark, T. E. Dever, J. J. Dever, P. Xu, V. Rehder, M. A. Sosa, and D. J. Baro Arthropod 5-HT2 Receptors: A Neurohormonal Receptor in Decapod Crustaceans That Displays Agonist Independent Activity Resulting from an Evolutionary Alteration to the DRY Motif J. Neurosci., March 31, 2004; 24(13): 3421 - 3435. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Roth, K. Baner, R. Westkaemper, D. Siebert, K. C. Rice, S. Steinberg, P. Ernsberger, and R. B. Rothman Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist PNAS, September 3, 2002; 99(18): 11934 - 11939. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Manivet, B. Schneider, J. C. Smith, D.-S. Choi, L. Maroteaux, O. Kellermann, and J.-M. Launay The Serotonin Binding Site of Human and Murine 5-HT2B Receptors. MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS J. Biol. Chem., May 3, 2002; 277(19): 17170 - 17178. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Ballesteros, L. Shi, and J. A. Javitch Structural Mimicry in G Protein-Coupled Receptors: Implications of the High-Resolution Structure of Rhodopsin for Structure-Function Analysis of Rhodopsin-Like Receptors Mol. Pharmacol., July 1, 2001; 60(1): 1 - 19. [Abstract] [Full Text] |
||||
![]() |
D. A. Shapiro, K. Kristiansen, W. K. Kroeze, and B. L. Roth Differential Modes of Agonist Binding to 5-Hydroxytryptamine2A Serotonin Receptors Revealed by Mutation and Molecular Modeling of Conserved Residues in Transmembrane Region 5 Mol. Pharmacol., November 1, 2000; 58(5): 877 - 886. [Abstract] [Full Text] |
||||
![]() |
K. Kristiansen, W. K. Kroeze, D. L. Willins, E. I. Gelber, J. E. Savage, R. A. Glennon, and B. L. Roth A Highly Conserved Aspartic Acid (Asp-155) Anchors the Terminal Amine Moiety of Tryptamines and Is Involved in Membrane Targeting of the 5-HT2A Serotonin Receptor But Does Not Participate in Activation via a "Salt-Bridge Disruption" Mechanism J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 735 - 746. [Abstract] [Full Text] |
||||
![]() |
M. M. Simpson, J. A. Ballesteros, V. Chiappa, J. Chen, M. Suehiro, D. S. Hartman, T. Godel, L. A. Snyder, T. P. Sakmar, and J. A. Javitch Dopamine D4/D2 Receptor Selectivity Is Determined by A Divergent Aromatic Microdomain Contained within the Second, Third, and Seventh Membrane-Spanning Segments Mol. Pharmacol., December 1, 1999; 56(6): 1116 - 1126. [Abstract] [Full Text] |
||||
![]() |
K. Wieland, A. M. T. Laak, M. J. Smit, R. Kuhne, H. Timmerman, and R. Leurs Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor J. Biol. Chem., October 15, 1999; 274(42): 29994 - 30000. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Roth, D. L. Willins, K. Kristiansen, and W. K. Kroeze Activation is Hallucinogenic and Antagonism is Therapeutic: Role of 5-HT2A Receptors in Atypical Antipsychotic Drug Actions Neuroscientist, July 1, 1999; 5(4): 254 - 262. [Abstract] [PDF] |
||||
![]() |
H.-L. Li, A. Galue, L. Meadows, and D. S. Ragsdale A Molecular Basis for the Different Local Anesthetic Affinities of Resting Versus Open and Inactivated States of the Sodium Channel Mol. Pharmacol., January 1, 1999; 55(1): 134 - 141. [Abstract] [Full Text] |
||||
![]() |
B. L. Roth, M. Shoham, M. S. Choudhary, and N. Khan Identification of Conserved Aromatic Residues Essential for Agonist Binding and Second Messenger Production at 5-Hydroxytryptamine2A Receptors Mol. Pharmacol., August 1, 1997; 52(2): 259 - 266. [Abstract] [Full Text] |
||||
![]() |
B. L. Roth, M. S. Choudhary, N. Khan, and A. Z. Uluer High-affinity Agonist Binding Is Not Sufficient for Agonist Efficacy at 5-Hydroxytryptamine2A Receptors: Evidence in Favor of a Modified Ternary Complex Model J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 576 - 583. [Abstract] [Full Text] |
||||
![]() |
N. Almaula, B. J. Ebersole, D. Zhang, H. Weinstein, and S. C. Sealfon Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor. Ser3.36(159) PROVIDES A SECOND INTERACTION SITE FOR THE PROTONATED AMINE OF SEROTONIN BUT NOT OF LYSERGIC ACID DIETHYLAMIDE OR BUFOTENIN J. Biol. Chem., June 21, 1996; 271(25): 14672 - 14675. [Abstract] [Full Text] [PDF] |
||||